Silk fibroin nanoparticles for celecoxib and curcumin delivery: ROS-scavenging and anti-inflammatory activities in an in vitro model of osteoarthritis

  • Barbara Crivelli
  • , Elia Bari
  • , Sara Perteghella
  • , Laura Catenacci
  • , Milena Sorrenti
  • , Michela Mocchi
  • , Silvio Faragò
  • , Giuseppe Tripodo
  • , Adriele Prina-Mello
  • , Maria Luisa Torre

Research output: Contribution to journalArticlepeer-review

Abstract

This paper aims at demonstrating silk fibroin nanoparticles (SFNs) promote anti-inflammatory properties of celecoxib (CXB) or curcumin (CUR), and could be exploited for osteoarthritis (OA) treatment. Nanoparticles were prepared by desolvation method and physico-chemically characterized (FT-IR, DSC, TGA, SEM, size distribution and drug release); empty and drug loaded nanoparticles were tested for their ROS-scavenging activity, hemolytic properties, cytotoxicity, and anti-inflammatory potency in an OA in vitro model. Results indicate that a controlled drug release has been achieved by varying the drug loading. Curcumin plus SFNs exhibited a synergistic antioxidant effect, while CXB was, in some manner, inhibitory. Both free drugs resulted highly cytotoxic while cell viability reached high values when encapsulated in SFNs. No appreciable differences in anti-inflammatory activity was evidenced between CUR loaded SFNs and CXB. In conclusion, SFNs is an optimal carrier to improve cyto- and hemo-compatibility of both CUR and CXB.

Original languageEnglish
Pages (from-to)37-45
Number of pages9
JournalEuropean Journal of Pharmaceutics and Biopharmaceutics
Volume137
DOIs
Publication statusPublished - Apr 2019
Externally publishedYes

Keywords

  • Celecoxib
  • Curcumin
  • Drug delivery systems
  • Nanoparticles
  • Osteoarthritis
  • Silk fibroin

Fingerprint

Dive into the research topics of 'Silk fibroin nanoparticles for celecoxib and curcumin delivery: ROS-scavenging and anti-inflammatory activities in an in vitro model of osteoarthritis'. Together they form a unique fingerprint.

Cite this